Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)

Recurrence in patients with glioblastoma (GBM) is inevitable resulting in short survival times, even in patients with O-6-Methylguanine-DNA Methyltransferase (MGMT) methylation. Other pathways must be activated to escape from temozolomide (TMZ) treatment, however acquired resistance mechanisms to TM...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, Wendy, Sevim-Nalkiran, Hatice, Zaman, Ashraf M., Matsuda, Kazuko, Khasraw, Mustafa, Nowak, Anna K., Chung, Liping, Baxter, Robert C., McDonald, Kerrie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393433/
https://www.ncbi.nlm.nih.gov/pubmed/30814573
http://dx.doi.org/10.1038/s41598-019-39427-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393433/
https://www.ncbi.nlm.nih.gov/pubmed/30814573
http://dx.doi.org/10.1038/s41598-019-39427-4

Ejemplares similares